

Best Available Copy

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 January 2001 (18.01.2001)


PCT

(10) International Publication Number
WO 01/03750 A1

- (51) International Patent Classification⁷: A61L 27/36, 27/34
- (21) International Application Number: PCT/US00/18461
- (22) International Filing Date: 6 July 2000 (06.07.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/350,386 9 July 1999 (09.07.1999) US
- (71) Applicant: ADVANCED TISSUE SCIENCES, INC.
[US/US]; 10933 North Torrey Pines Road, La Jolla, CA 92037-1005 (US).
- (72) Inventors: NAUGHTON, Gail, K.; 10933 North Torrey Pines Road, La Jolla, CA 92037-1005 (US). ZELTINGER, Joan; 4136 Camino Ticino, San Diego, CA 92122 (US).
- (74) Agents: CORUZZI, Laura, A. et al.; Pennic & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: HUMAN NATURALLY SECRETED EXTRACELLULAR MATRIX-COATED DEVICE



(57) Abstract: The present invention discloses compositions comprising a naturally secreted human extracellular matrix and methods for the use thereof. More particularly, the present invention provides compositions and methods for the repair of skin defects using natural human extracellular matrix by injection. The present invention also provides prosthetic devices which are coated or sealed with a composition comprising a naturally secreted extracellular matrix and methods for the use thereof.

WO 01/03750 A1



patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

Published:

— *With international search report.*

HUMAN NATURALLY SECRETED EXTRACELLULAR MATRIX-COATED DEVICE

This application is a continuation-in-part
5 application of United States Patent Application Serial No.
08/660,787 filed June 6, 1996, which is a continuation-in-
part of United States Patent Application Serial No.
08/470,101 filed June 6, 1995, now U.S. Patent No. 5,830,708,
each of which is incorporated by reference herein in its
entirety.
10

1. INTRODUCTION

The present invention is directed to a human
naturally secreted extracellular matrix composition, as well
as methods for the production and use thereof. In
15 particular, the present invention is directed to methods of
soft tissue repair by injecting a formulated human naturally
secreted extracellular matrix composition into a subject in
need thereof. The present invention is also directed to a
formulated human naturally secreted extracellular matrix
20 composition-coated prosthetic device for implantation into a
subject, preferably a human, and more particularly to a
prosthetic device such as a vascular graft or stent coated
with a formulated human naturally secreted extracellular
matrix composition of the present invention.

25

2. BACKGROUND OF THE INVENTION

The idea of using an injectable material for soft
tissue augmentation and repair developed soon after the
invention of the hypodermic needle. Various products have
been injected into the human body for correction of soft
30 tissue and skin defects including paraffin, petrolatum,
vegetable oils, lanolin, bees wax, and silicone. Injectable
liquid silicone has been used extensively, however, due to

long term side effects, such as nodules, recurring cellulitis and skin ulcers which are now being followed more closely, the use of injectable silicone is on the decline. Further, in the State of Nevada it is a felony to use injectable
5 silicone in a human. Orange, Skin and Allergy News (1992) Vol.23, No.6, pg. 1. More recently, bovine collagen has gained widespread use as an injectable material for soft tissue augmentation. Collagen is the principal extracellular structural protein of the animal body. At least fourteen
10 types of mammalian collagen have been described. The common characteristic amongst them is a three stranded helix, consisting of three polypeptide chains, called alpha-chains. All alpha-chains have the same configuration, but differ in the composition and sequence of their amino acids. Although this leads to different types of alpha-chains, however, they
15 all have glycine at every third position in the amino acid sequence. The glycine at every third position allows for the helical structure of the alpha-chains. Type I collagen is composed of two alpha₁-chains and one alpha₂-chain and is the principal extracellular material of skin, tendon and bone.
20 When clinicians mention "collagen", they are usually referring to type I collagen. See Table I, *infra*, for a detailed listing of collagen types I-V and in which tissues they are found.

Collagen has been used as an implant material to
25 replace or augment hard or soft connective tissue, such as skin, tendon, cartilage, bone and interstitium. Additionally, collagen implants have been used for cosmetic purposes for a number of years since collagen can help cellular ingrowth at the placement site. Early collagen implants were often solid collagen masses which were cross-
30 linked with chemical agents, radiation or other means to improve mechanical properties, decrease immunogenicity and/or increase resistance to resorption. The collagen utilized was

in a variety of forms, including cross-linked and non-cross-linked fibrillar collagens, gelatins, and the like and sometimes was combined with various other components, such as lubricants, osteogenic factors and the like, depending on use. A major disadvantage of solid cross-linked collagen implants is the requirement for surgical implantation by means of incision. In addition, lack of deformability and flexibility are other disadvantages of solid collagen implants.

Oliver et al., Clinical Orthopaedics & Related Research (1976) 115:291-302; Br. J. Exp. Path. (1980) 61:544-549; and Conn. Tissue Res. (1981) 9:59-62 describe implants made by treating skin with trypsin followed by cross-linking with an aldehyde. The resulting solid collagen implants were reported to maintain their original mass after prolonged implantation. A main problem with such solid implants is that they must be implanted surgically. Other disadvantages are that they are not as deformable as injectable implants and residual glutaraldehyde may cause the implant to lose its flexibility due to continuing cross-linking in situ.

Schechter, et al., Br. J. Plas. Surg. (1975) 28:198-202 disclose glutaraldehyde cross-linked skin that was soaked in L-alanine after cross-linking. The article postulates that the exposure of the skin to L-alanine blocked residual reactive groups of the aldehyde, thereby preventing the release of toxic molecules generated by such groups.

An alternative to surgically implanted solid collagen material is disclosed in U.S. Pat. No. 3,949,073. U.S. Patent No. 3,949,073 describes the use of atelopeptide solutions of bovine collagen as an injectable implant material for augmenting soft tissue. According to the patent, the bovine collagen is reconstituted before implantation and forms a fibrous mass of tissue when

implanted. The patent suggests adding particles of insoluble bovine collagen microfibrils to control the shrinkage of the fibrous mass formed at the augmentation site. The commercial embodiment of the material described in the patent is
5 composed of reconstituted atelopeptide bovine collagen in saline that contains a small amount of local anesthetic. While effective, the implant shrinks in volume after implantation due primarily to absorption of its fluid component by the body. Thus, if volume consistency is essential, an additional injection or injections of
10 supplemental implant material is required. This specific composition has many serious drawbacks, e.g., the collagen is from a bovine source, not human, and the preparation process is not only lengthy and expensive but also requires the addition of microfibrils.

15 U.S. Patent No. 4,424,208 describes an injectable dispersion of cross-linked atelopeptide bovine collagen and reconstituted atelopeptide bovine collagen fibers in an aqueous carrier which exhibited improved volume consistency over the material of U.S. Pat. No. 3,949,073.

20 U.S. Patent No. 4,582,640 discloses an improved injectable implant over U.S. Pat. Nos. 3,949,073 and 4,424,208 in which the improvement consists of improved volume consistency and resistance to physical deformation, improved injectability as compared to the dispersion of U.S. Pat. No. 4,424,208 and that the bovine collagen contains only
25 a single physical form of collagen as compared to the two physical forms found in U.S. Pat. No. 4,424,208.

U.S. Patent No. 4,803,075 describes bovine collagen compositions including a lubricant material to enhance injectability through narrow diameter needles for soft tissue
30 repair.

Despite the advantages and overall usefulness of the injectable collagen implant materials disclosed above,

problems associated with producing and injecting the materials have been encountered. For example, for soft tissue repair, suspensions of fibrillar collagen have often been used by injecting the composition to a treatment site through a fine gauge needle. The use of fibrillar collagen as the primary matrix material in injectable soft and hard tissue implant compositions has several limitations. The preparation of fibrillar collagen suitable for human use is relatively time consuming and expensive. In particular, the complete removal of contaminating and potentially immunogenic substances to produce atelocollagen is a relatively complex and expensive procedure. Moreover, the persistence, shape retention, cohesiveness, stability, elasticity, toughness and intrudability of the fibrillar collagen compositions are not optimal.

15 In addition to the problems associated with producing and injecting the collagen implant materials, problems with the actual use of the above mentioned patented injectable implants are also abundant. For instance, since the above patented injectables derive collagen from xenogeneic sources, usually bovine collagen, the collagen must be modified to reduce its immunogenicity. Even with modified collagen, the implant material is still quite immunogenic to which some people are either already naturally allergic or develop an allergic reaction over time to the bovine collagen. Due to these allergic reactions the injectable collagen implants described above cannot be given to many people and others are limited to receiving only three injections per year. Severe allergic reactions include symptoms of rheumatoid arthritis, while less severe reactions include redness and swelling at the site of injection which may lead to permanent scarring. Because of these severe side effects, the above described collagen injectables are no longer used for lip augmentation. Further, the problems

associated with injecting xenogeneic collagen seem so intractable that rather than injecting collagen, biocompatible ceramic matrices have been injected to achieve similar results as described in U.S. Patent No. 5,204,382.

5 In summary, due to the shortcomings of the above-described injectable compositions for the repair of soft tissue defects, such as the lack of persistence, the need for repeated injections and serious concern over adverse reactions, newer injectable materials for soft tissue augmentation are needed.

10

3. SUMMARY OF THE INVENTION

The present invention relates to injectable materials for soft tissue augmentation and methods for use and manufacture of the same, which overcome the shortcomings of bovine injectable collagen and other injectable materials, including silicone, of the prior art. The injectable materials used in accordance with the present invention comprise naturally secreted extracellular matrix preparations as well as preparations derived from naturally secreted extracellular matrix. These preparations are biocompatible, biodegradable and are capable of promoting connective tissue deposition, angiogenesis, reepithelialization and fibroplasia, which is useful in the repair of skin and other tissue defects. These extracellular matrix preparations may be used to repair tissue defects by injection at the site of the defect.

25 The injectable preparations of the present invention have many advantages over conventional injectable collagen preparations used for the repair of skin defects. The extracellular matrix preparations of the present invention contain only human proteins, therefore, there is a reduced risk of an immune response due to foreign, e.g., xenogeneic, proteins or peptides, especially the type of

30

immune response seen with bovine collagen found in conventional injectable collagen preparations. Additionally, the injected preparations of the present invention should persist longer, and, even if multiple injections are
5 required, the injections should not be subject to the "no more than three injections per year" rule of bovine collagen-based preparations due to the lack of immunogenicity. Another advantage provided by the present invention is that the preparations of naturally secreted extracellular matrix contain a mixture of extracellular matrix proteins that
10 closely mimics the compositions under physiologically normal conditions; for example, in an extracellular matrix derived from dermal cells, type I and III collagens, hyaluronic acid as well as various glycosaminoglycans and natural growth factors are present. Many of these extracellular matrix
15 proteins and growth factors have been studied extensively and have been shown to be critical for wound healing and tissue restoration.

The present invention also relates to a prosthetic device suitable for use or implantation into a subject,
20 preferably a human. The device is coated with a formulated human naturally secreted extracellular matrix composition. The device, for example, is a annuloplasty ring, heart sewing ring, stent, artificial joint, artificial heart, etc. In another embodiment, the device is a suture material, gauze pad or an adhesive or non-adhesive bandage. The formulated
25 materials used in accordance with the present invention comprise human naturally secreted extracellular matrix preparations as well as preparations derived from human naturally secreted extracellular matrix. These compositions are biocompatible, biodegradable and are capable of promoting
30 connective tissue deposition, angiogenesis, reepithelialization and fibroplasia, which is useful in the promotion of wound healing and tissue regeneration. The

present invention also provides new and advantageous processes for generating the extracellular matrix coated devices suitable for implantation.

The devices of the present invention have many advantages over conventional devices used for wound repair or in surgery. The extracellular matrix preparations of the present invention which coat or seal the device contain only human proteins, therefore, there is a reduced risk of an immune response due to foreign, e.g., xenogeneic, proteins or peptides. Another advantage provided by the present invention is that the preparations of naturally secreted extracellular matrix contain a mixture of extracellular matrix proteins which closely mimics the compositions under physiologically normal conditions, for example, in an extracellular matrix derived from dermal cells, type I and III collagens, hyaluronic acid as well as various glycosaminoglycans and natural growth factors are present. Many of these extracellular matrix proteins and growth factors have been studied extensively and have been shown to be critical for wound healing and tissue restoration and regeneration. In a specific embodiment, the extracellular matrix is formulated with a drug, e.g., an antibiotic, angiogenesis factor, other therapeutic agent., such that the implantable device coated with the formulated matrix also acts as a drug delivery system. In one embodiment of the present invention, the composition is an autologous composition prepared according to the methods of the invention using cells or tissues obtained from the subject in which the device is to be implanted.

In another embodiment of the invention, the matrix preparations can be used in highly improved systems of *in vitro* tissue culture. In this embodiment, naturally secreted extracellular matrix coated three-dimensional frameworks can be used to culture cells, which require attachment to a

support in order to grow, but do not attach to conventional tissue culture vessels. In addition to culturing cells on a coated framework, the extracellular matrix secreted by the cells onto the framework can be collected and used to coat vessels used in tissue culture. The extracellular matrix, acting as a base substrate, may allow cells normally unable to attach to conventional tissue culture dish base substrates to attach and subsequently grow.

Yet another embodiment of the present invention is directed to a novel method for determining the ability for cellular taxis of a particular cell. The method involves inoculating one end of a naturally secreted extracellular matrix coated three-dimensional framework with the cell type in question and over time measure the distance traversed across the framework by the cell. Because the extracellular matrix is secreted naturally by the cells onto the framework, it is an excellent *in vitro* substitute of extracellular matrix found in the body. Such an assay, for example, may inform whether isolated tumor cells are metastatic or whether certain immune cells can migrate, or even chemotact, across the framework, thus, indicating that the cell has such cellular taxis ability.

3.1. DEFINITIONS AND ABBREVIATIONS

The following terms used herein shall have the meanings indicated:

Adherent Layer:

cells attached directly to the three-dimensional framework or connected indirectly by attachment to cells that are themselves attached directly to the matrix.

Naturally Secreted:

in context of a naturally secreted three-dimensional extracellular matrix, naturally

secreted means that the extracellular matrix is secreted by cells growing in three dimensions as opposed to cells growing in monolayer culture, such that the matrix composition secreted by the cells more closely resembles the matrix as secreted by cells in vivo.

Pharmaceutically Acceptable Carrier:

an aqueous medium at physiological isotonicity and pH and may contain other elements such as local anesthetics and/or fluid lubricants.

Stromal Cells:

fibroblasts with or without other cells and/or elements found in loose connective tissue, including but not limited to, endothelial cells, pericytes, macrophages, monocytes, plasma cells, mast cells, adipocytes, chondrocytes, etc.

Three-Dimensional Framework:

a three dimensional support composed of any material and/or shape that (a) allows cells to attach to it (or can be modified to allow cells to attach to it); and (b) allows cells to grow in more than one layer. This support is inoculated with stromal cells to form the living stromal matrix.

Living Stromal Tissue:

a three dimensional framework which has been inoculated with stromal cells. Whether confluent or subconfluent, stromal cells according to the invention continue to grow and divide. The living stromal tissue prepared in vitro is the source of the extracellular matrix proteins used in the injectable formulations of the invention.

The following abbreviations shall have the meanings indicated:

EDTA ethylene diamine tetraacetic acid

FBS fetal bovine serum

HBSS Hank's balanced salt solution

HS horse serum

5 MEM minimal essential medium

PBS phosphate buffered saline

RPMI 1640 Roswell Park Memorial Institute Medium No.
1640 (GIBCO, Inc., Grand Island, NY)

SEM scanning electron microscopy

10 The present invention may be more fully understood
by reference to the following detailed description, examples
of specific embodiments and appended figures, which are
offered for purposes of illustration only and not by way of
limitation.

15 4. BRIEF DESCRIPTION OF THE FIGURES

FIGURE 1. Figure 1 is a scanning electron
micrograph depicting fibroblast attachment to the
three-dimensional matrix and extension of cellular processes
across the mesh opening. Fibroblasts are actively secreting
20 matrix proteins and are at the appropriate stage of
subconfluency which should be obtained prior to inoculation
with tissue-specific cells.

FIGURE 2A-D. Figures 2A-D are transmission
electron micrographs of collagen isolated from extracellular
matrix prepared from dermal tissue grown in vitro (Figure 2A-
25 B) or from a normal adult human dermal sample (Figure 2C-D).

5. DETAILED DESCRIPTION OF THE INVENTION

One embodiment of the present invention involves
the preparation and use of an injectable extracellular matrix
30 composition for the treatment of skin defects. The
extracellular matrix proteins are derived from a living
stromal tissue prepared in vitro by growing stromal cells on

a three-dimensional framework resulting in a multi-layer cell culture system. In conventional tissue culture systems, cells are grown in a monolayer. Cells grown on a three-dimensional framework support, in accord with the present invention, grow in multiple layers, forming a cellular matrix. This matrix system approaches physiologic conditions found *in vivo* to a greater degree than previously described monolayer tissue culture systems. The three-dimensional cell culture system is applicable to the proliferation of different types of stromal cells and formation of a number of different stromal tissues, including but not limited to, dermis, bone marrow stroma, glial tissue, cartilage, etc.

In accordance with the present invention, the pre-established living stromal tissue comprises stromal cells grown on a three-dimensional framework or network. The stromal cells can comprise fibroblasts with or without additional cells and/or elements described more fully herein. The fibroblasts and other cells and/or elements that comprise the stroma can be fetal or adult in origin, and can be derived from convenient sources such as skin, liver, pancreas, etc. Such tissues and/or organs can be obtained by appropriate biopsy or upon autopsy. In fact, cadaver organs may be used to provide a generous supply of stromal cells and elements.

Once inoculated onto the three-dimensional framework, the stromal cells will proliferate on the framework, and elaborate growth factors, regulatory factors and extracellular matrix proteins that are deposited on the support. The living stromal tissue will sustain active proliferation of the culture for long periods of time. Growth and regulatory factors can be added to the culture, but are not necessary since they are elaborated by the stromal support matrix. Methods and apparatus for preparing

such living three-dimensional stromal tissues and resulting compositions, such as vascular graft compositions, can be found in United States Patent Nos. 4,963,489; 5,266,480; and 5,792,603, each of which is incorporated by reference herein
5 in its entirety.

The naturally secreted extracellular matrix is collected from the three-dimensional framework and is processed further with a pharmaceutically acceptable carrier and placed in a syringe for precise placement of the biomaterial into tissues, such as the facial dermis, or into
10 the sac of an aneurysm. The injectable compositions are also useful for the repair of spinal and craniofacial defects.

In another embodiment of the present invention, the naturally secreted extracellular matrix is collected from the three-dimensional framework and is processed further for
15 coating or sealing a prosthetic device which is suitable, e.g., for implantation into a subject, preferably a human. Examples of such devices include, but are not limited to, a stent, graft, stent/graft, synthetic graft, tissue engineered vascular graft, as well as sewing and annuloplasty rings used
20 in cardiac valve reconstruction and replacement. Further, such devices may be constructed from metal or plastic or biopolymers. In yet another embodiment, the extracellular matrix is used to coat or seal internal or external surgical sutures, as well as for coating Band-Aid®-type adhesive bandages and other wound healing coverings, e.g., non-
25 adhesive gauze.

The present invention is based, in part, on the discovery that during the growth of human stromal cells on a biodegradable or non-biodegradable three-dimensional support framework, the cells synthesize and deposit on the
30 three-dimensional support framework a human extracellular matrix as produced in normal human tissue. The extracellular matrix is secreted locally by cells and not only binds cells

and tissues together but also influences the development and behavior of the cells it contacts. The extracellular matrix contains various fiber-forming proteins interwoven in a hydrated gel composed of a network of glycosaminoglycan chains. The glycosaminoglycans are a heterogeneous group of long, negatively charged polysaccharide chains, which (except for hyaluronic acid) are covalently linked to protein to form proteoglycan molecules.

The fiber-forming proteins are of two functional types: (a) mainly structural (collagens and elastin), and (b) mainly adhesive (such as fibronectin and laminin). The fibrillar collagens (types I, II, and III) are rope-like, triple-stranded helical molecules that aggregate into long cable-like fibrils in the extracellular space; these in turn can assemble into a variety of highly ordered arrays. Type IV collagen molecules assemble into a sheetlike meshwork that forms the core of all basal laminae. Elastin molecules form an extensive cross-linked network of fibers and sheets that can stretch and recoil, imparting elasticity to the matrix. Fibronectin and laminin are examples of large adhesive glycoproteins in the matrix; fibronectin is widely distributed in connective tissues, whereas laminin is found mainly in basal laminae. By means of their multiple binding domains, such proteins help cells adhere to and become organized by the extracellular matrix.

As an example, a naturally secreted human dermal extracellular matrix contains type I and type III collagens, fibronectin, tenascin, glycosaminoglycans, acidic and basic FGF, TGF- α and TGF- β , KGF, decorin and various other secreted human dermal matrix proteins. As naturally secreted products, the various extracellular matrix proteins are produced in the quantities and ratios similar to that existing *in vivo*. Moreover, growth of the stromal cells in three dimensions will sustain active proliferation of cells

in culture for much longer time periods than will monolayer systems. Further, the three-dimensional system supports the maturation, differentiation, and segregation of cells in culture *in vitro* to form components of adult tissues
5 analogous to counterparts found *in vivo*. Thus, the extracellular matrix created by the cells in culture is more analogous to native tissues.

Although the applicants are under no duty or obligation to explain the mechanism by which the invention works, a number of factors inherent in the three-dimensional
10 culture system may contribute to these features of the three dimensional culture system:

- (a) The three-dimensional framework provides a greater surface area for protein attachment, and consequently, for the adherence of stromal cells.
- 15 (b) Because of the three-dimensionality of the framework, stromal cells continue to actively grow in contrast to cells in monolayer cultures, which grow to confluence, exhibit contact inhibition, and cease to grow and divide. The elaboration of
20 growth and regulatory factors by replicating stromal cells may be partially responsible for stimulating proliferation and regulating differentiation of cells in culture.
- (c) The three-dimensional framework allows for a spatial distribution of cellular elements which is
25 more analogous to that found in the counterpart tissue *in vivo*.
- (d) The increase in potential volume for cell growth in the three-dimensional system may allow the establishment of localized microenvironments
30 analogous to native counterparts found *in vivo*.
- (e) The three-dimensional matrix maximizes cell-cell interactions by allowing greater potential for

movement of migratory cells, such as macrophages, monocytes and possibly lymphocytes in the adherent layer.

- 5 (f) It has been recognized that maintenance of a differentiated cellular phenotype requires not only growth/differentiation factors but also the appropriate cellular interactions. The present invention effectively recreates the stromal tissue microenvironment.

10 The three-dimensional stromal support, the culture system itself, and its maintenance, as well as various uses of the three-dimensional cultures and of the naturally secreted extracellular matrix are described in greater detail in the subsections below. Solely for ease of explanation, the detailed description of the invention is divided into the
15 three sections, (i) growth of the three-dimensional stromal cell culture, (ii) isolation of the naturally secreted human extracellular matrix, and (iii) formulation of the isolated extracellular matrix into preparations for injection at the site of soft tissue defects and into preparations for coating
20 or sealing a prosthetic device.

5.1. PREPARING THE LIVING STROMAL TISSUE IN VITRO

The three-dimensional support used to culture stromal tissue may be of any material and/or shape that:

- 25 (a) allows cells to attach to it (or can be modified to allow cells to attach to it); and
(b) allows cells to grow in more than one layer.

A number of different materials may be used to form the framework, such as non-biodegradable or biodegradable
30 materials. For example, non-biodegradable materials include but are not limited to: nylon (polyamides), dacron (polyesters), polystyrene, polypropylene, polyacrylates,

polyvinyl compounds (e.g., polyvinylchloride), polycarbonate (PVC), polytetrafluorethylene (PTFE; teflon), thermanox (TPX), polymethylmethacrylate, polyethylene, poly(ethylene terephthalate), polyalkylene oxalates, polyurethanes, 5 polysiloxanes, poly(dimethyl siloxane), polycyanoacrylates, polyphosphazenes, poly(amino acids), ethylene glycol I dimethacrylate, poly(methyl methacrylate), poly(2-hydroxyethyl methacrylate), poly(HEMA), polyhydroxyalkanoates, etc. Additionally, biodegradable material may also be utilized, including but not limited to: 10 nitrocellulose, cotton, polyglycolic acid (PGA), cat gut sutures, cellulose, gelatin, dextran, collagen, chitosan, hyaluronic acid, alginate, poly(glycolide-lactide) copolymer, polylactic acid, poly(ϵ -caprolactone), poly(β -hydroxybutyrate), polydioxanone, poly(γ -ethyl glutamate), 15 polyiminocarbonates, poly(ortho ester), polyanhydrides, etc. Any of these materials, bio- or non-biodegradable, can be, e.g., woven into a mesh, or knitted or braided into a rope-like scaffold, or cast or printed, to form a three-dimensional framework. Alternatively, the materials 20 can be used to form other types of three-dimensional frameworks, for example, a sponge with interconnected pores of about less than 90 to 700 microns, such as collagen sponges.

Certain materials, such as nylon, polystyrene, etc., are poor substrates for cellular attachment. When 25 these materials are used as the three-dimensional support framework, it is advisable to pre-treat the framework prior to inoculation of stromal cells in order to enhance the attachment of stromal cells to the framework. For example, prior to inoculation with stromal cells, nylon frameworks can 30 be treated with 0.1 M acetic acid, and incubated in polylysine, FBS, and/or collagen to coat the nylon. Polystyrene can be similarly treated using sulfuric acid. A

convenient nylon mesh which can be used in accordance with the invention is Nitex, a nylon filtration mesh having an average pore size of 210 μm and an average nylon fiber diameter of 90 μm (#3-210/36, Tetko, Inc., N.Y.).

5 Stromal cells comprising fibroblasts derived from adult or fetal tissue, with or without other cells and elements described below, are inoculated onto the framework. These fibroblasts may be derived from organs, such as skin, liver, pancreas, etc. which can be obtained by biopsy, where appropriate, or upon autopsy. In fact, fibroblasts can be
10 obtained in quantity rather conveniently from any appropriate cadaver organ. In a preferred embodiment, fetal fibroblasts can be obtained in high quantity from foreskin.

Fibroblasts may be readily isolated by disaggregating an appropriate organ or tissue which is to
15 serve as the source of the fibroblasts. This can be readily accomplished using techniques known to those skilled in the art. For example, the tissue or organ can be disaggregated mechanically and/or treated with digestive enzymes and/or chelating agents that weaken the connections between
20 neighboring cells making it possible to disperse the tissue into a suspension of individual cells without appreciable cell breakage. Enzymatic dissociation can be accomplished by mincing the tissue and treating the minced tissue with any of a number of digestive enzymes either alone or in combination. Such enzymes include, but are not limited to, trypsin,
25 chymotrypsin, collagenase, elastase, hyaluronidase, DNase, pronase, and/or dispase etc. Mechanical disruption can also be accomplished by a number of methods including, but not limited to the use of grinders, blenders, sieves, homogenizers, pressure cells, or insonators to name but a
30 few. For a review of tissue disaggregation techniques, see Freshney, Culture of Animal Cells. A Manual of Basic Technique, 2d Ed., A.R. Liss, Inc., New York, 1987, Ch. 9,

pp. 107-126.

Once the tissue has been reduced to a suspension of individual cells, the suspension can be fractionated into subpopulations from which the fibroblasts and/or other stromal cells and/or elements can be obtained. This also may be accomplished using standard techniques for cell separation including, but not limited to, cloning and selection of specific cell types, selective destruction of unwanted cells (negative selection), separation based upon differential cell agglutinability in the mixed population, freeze-thaw procedures, differential adherence properties of the cells in the mixed population, filtration, conventional and zonal centrifugation, centrifugal elutriation (counter-streaming centrifugation), unit gravity separation, countercurrent distribution, electrophoresis and fluorescence-activated cell sorting. For a review of clonal selection and cell separation techniques, see Freshney, Culture of Animal Cells. A Manual of Basic Techniques, 2d Ed., A.R. Liss, Inc., New York, 1987, Ch. 11 and 12, pp. 137-168.

The isolation of fibroblasts, for example, can be carried out as follows: fresh tissue samples are thoroughly washed and minced in Hanks' balanced salt solution (HBSS) in order to remove serum. The minced tissue is incubated from 1-12 hours in a freshly prepared solution of a dissociating enzyme such as trypsin. After such incubation, the dissociated cells are suspended, pelleted by centrifugation and plated onto culture dishes. All fibroblasts will attach before other cells, therefore, appropriate stromal cells can be selectively isolated and grown. The isolated fibroblasts can then be grown to confluency, lifted from the confluent culture and inoculated onto the three-dimensional framework, see Naughton et al., 1987, J. Med. 18(3&4):219-250. Inoculation of the three-dimensional framework with a high concentration of stromal cells, e.g., approximately 10^6 to 5×10^6

x 10⁷ cells/ml, will result in the establishment of the three-dimensional stromal support in shorter periods of time.

In addition to fibroblasts, other cells can be added to form the three-dimensional stromal cell culture-
5 producing extracellular matrix. For example, other cells found in loose connective tissue may be inoculated onto the three-dimensional support framework along with fibroblasts. Such cells include, but are not limited to, endothelial cells, pericytes, macrophages, monocytes, plasma cells, mast
10 cells, adipocytes, chondrocytes, etc. These other cells can be readily derived from appropriate organs such as skin, liver, etc., using methods known, such as those discussed above.

In one embodiment of the present invention, stromal cells, which are specialized for the particular tissue to be
15 cultured, can be added to the fibroblast stroma for the production of a tissue type specific extracellular matrix. For example, dermal fibroblasts can be used to form the three-dimensional subconfluent stroma for the production of skin-specific extracellular matrix *in vitro*. Alternatively,
20 stromal cells of hematopoietic tissue including, but not limited to, fibroblast endothelial cells, macrophages/monocytes, adipocytes and reticular cells, can be used to form the three-dimensional subconfluent stroma for the production of a bone marrow-specific extracellular matrix *in vitro*, see *infra*. Hematopoietic stromal cells can be
25 readily obtained from the "buffy coat" formed in bone marrow suspensions by centrifugation at low forces, e.g., 3000x g. Stromal cells of liver may include fibroblasts, Kupffer cells, and vascular and bile duct endothelial cells. Similarly, glial cells can be used as the stroma to support
30 the proliferation of neurological cells and tissues. Glial cells for this purpose can be obtained by trypsinization or collagenase digestion of embryonic or adult brain. Ponten

and Westermarck, 1980, In Federof, S. Hertz, L., eds, "Advances in Cellular Neurobiology," Vol.1, New York, Academic Press, pp.209-227.

For certain uses *in vivo* it is preferable to obtain
5 the stromal cells from the subject's own tissues. The growth
of cells in the presence of the three-dimensional stromal
support framework can be further enhanced by adding to the
framework, or coating the framework support with natural or
recombinant molecules, including but not limited to,
10 proteins, such as collagens, elastic fibers, reticular
fibers, and glycoproteins; glycosaminoglycans, such as
heparin sulfate, chondroitin-4-sulfate,
chondroitin-6-sulfate, dermatan sulfate, keratan sulfate,
etc.; a cellular matrix, and/or other materials, such as
whole blood, serum, growth factors, fibronectin, Pronectin F,
15 RGD peptide, or cell or tissue extracts.

After inoculation of the stromal cells, the
three-dimensional framework is incubated in an appropriate
nutrient medium under physiologic conditions favorable for
cell growth, *i.e.*, promoting mitosis (cell division). Many
20 commercially available media such as RPMI 1640, Fisher's,
Iscoe's, McCoy's, and the like, may be suitable for use. It
is important that the three-dimensional stromal culture be
suspended or floated in the medium during the incubation
period in order to maximize proliferative activity. In
addition, the culture should be "fed" periodically to remove
25 the spent media, depopulate released cells, and to add fresh
media.

During the incubation period, the stromal cells
will grow linearly along and envelop the three-dimensional
framework before beginning to grow into the openings of the
30 framework. The cells are grown to an appropriate degree to
allow for adequate deposition of extracellular matrix
proteins..

The openings of the framework should be of an appropriate size to allow the stromal cells to stretch across the openings. Maintaining actively growing stromal cells which stretch across the framework enhances the production of growth factors which are elaborated by the stromal cells, and hence, will support long term cultures. For example, if the openings are too small, the stromal cells may rapidly achieve confluence but be unable to easily exit from the mesh. Trapped cells can exhibit contact inhibition and cease production of the appropriate factors necessary to support proliferation and maintain long term cultures. If the openings are too large, the stromal cells are unable to stretch across the opening. This will also decrease stromal cell production of the appropriate factors necessary to support proliferation and maintain long term cultures.

When using a mesh type of matrix, as exemplified herein, it has been found that openings ranging from about 150 μm to about 220 μm will work satisfactorily. However, depending upon the three-dimensional structure and intricacy of the framework, other sizes work equally well. In fact, any shape or structure that allows the stromal cells to stretch and continue to replicate and grow for lengthy time periods will work in accordance with the present invention.

Different proportions of the various types of collagen deposited on the framework can be achieved by inoculating the framework with different tissue-specific cells. For example, for hematopoietic cells, the secreted matrix contains collagen types III, IV and I in an approximate ratio of 6:3:1. For skin cells, collagen types I and III are deposited in the matrix. The proportions of collagen types deposited can be manipulated or enhanced by selecting fibroblasts which elaborate the appropriate extracellular matrix proteins. This can be accomplished using monoclonal antibodies of an appropriate isotype or

subclass which are capable of activating complement, and which define particular collagen types. These antibodies in combination with complement can be used to negatively select the fibroblasts which express the desired collagen type.

5 Alternatively, the stroma used to inoculate the framework can be a mixture of cells which synthesize the appropriate collagen types desired. The distribution and origins of the five types of collagen is shown in Table I.

10

TABLE I

DISTRIBUTIONS AND ORIGINS OF
VARIOUS TYPES OF COLLAGEN

	Collagen Type	Principal Tissue Distribution	Cells of Origin
15	I	Loose and dense ordinary connective tissue; collagen fibers	Fibroblasts and reticular cells; smooth muscle cells
		Fibrocartilage	
		Bone	Osteoblast
		Dentin	Odontoblasts
20	II	Hyaline and elastic cartilage	Chondrocytes
		Vitreous body of eye	Retinal cells
	III	Loose connective tissue; reticular fibers	Fibroblasts and reticular cells
25		Papillary layer of dermis	
		Blood vessels	Smooth muscle cells; endothelial cells
30	IV	Basement membranes	Epithelial and endothelial cells
		Lens capsule of eye	Lens fibers

WO 01/03750

5	V	Fetal membranes; placenta	Fibroblast
		Basement membranes	
		Bone	
		Smooth muscle	Smooth muscle cells
10	VI	Connective Tissue	Fibroblasts
	VII	Epithelial basement membranes, anchoring fibrils	Fibroblasts, keratinocytes
	VIII	Cornea	Corneal fibroblasts
	IX	Cartilage	
15	X	Hypertrophic cartilage	
	XI	Cartilage	
	XII	Papillary dermis	Fibroblasts
	XIV, undulin	Reticular dermis	Fibroblasts
20	XVII	P170 bullous pemphigoid antigen	Keratinocytes

Thus, depending upon the collagen types desired, the appropriate stromal cell(s) can be selected to inoculate the three-dimensional framework.

25 The three-dimensional extracellular matrix producing culture of the present invention affords a vehicle for introducing gene products in vivo. In certain situations, it may be desirable to prepare an extracellular matrix containing a foreign gene product, growth factor, regulatory factor, etc. In such cases, the cells may be
30 genetically engineered to express the gene product, or altered forms of the gene product that are immobilized in the extracellular matrix laid down by the stromal cells. For

example, using recombinant DNA techniques, a gene of interest can be placed under the control of an inducible promoter. The recombinant DNA construct containing the gene can be used to transform or transfect a host cell which is cloned and
5 then clonally expanded in the three-dimensional culture system. The use of the three-dimensional culture in this regard has a number of advantages. First, since the culture comprises eukaryotic cells, the gene product will be properly expressed and processed in culture to form an active product. Second, the number of transfected cells can be substantially
10 enhanced to be of clinical value, relevance, and utility. The three-dimensional cultures of the present invention allow for expansion of the number of transfected cells and amplification (via cell division) of transfected cells.

Preferably, the expression control elements used
15 should allow for the regulated expression of the gene so that the product can be over synthesized in culture. The transcriptional promoter chosen generally, and promoter elements specifically, depends, in part, upon the type of tissue and cells cultured. Cells and tissues which are
20 capable of secreting proteins (e.g., those characterized by abundant rough endoplasmic reticulum and golgi complex) are preferable.

During incubation of the three-dimensional culture, proliferating cells are released from the framework. These released cells can stick to the walls of the culture vessel
25 where they can continue to proliferate and form a confluent monolayer. This should be prevented or minimized, for example, by removal of the released cells during feeding, or by transferring the three-dimensional framework to a new culture vessel. The presence of a confluent monolayer in the
30 vessel will "shut down" the growth of cells in the three-dimensional framework and/or culture. Removal of the confluent monolayer or transfer of the stromal culture to

fresh media in a new vessel will restore proliferative activity of the three-dimensional culture system. Such removal or transfers should be done in any culture vessel which has a stromal monolayer exceeding 25% confluency.

5 Alternatively, the culture system can be agitated to prevent the released cells from sticking, or instead of periodically feeding the cultures, the culture system could be set up so that fresh media continuously flows through the system. The flow rate can be adjusted to both maximize proliferation within the three-dimensional culture, and to wash out and

10 remove cells released from the matrix, so that they will not stick to the walls of the vessel and grow to confluence. In any case, the released stromal cells can be collected and crypreserved for future use.

Once inoculated onto the three-dimensional

15 framework, adherence of the fibroblasts is seen quickly (e.g., within hours) and the fibroblasts begin to stretch across the framework openings within days. These fibroblasts are metabolically active, secrete extracellular matrix and rapidly form a dermal equivalent consisting of active

20 fibroblasts and collagen.

Figure 1 illustrates the ability of the fibroblasts to arrange themselves into parallel layers between the naturally-secreted collagen bundles. These fibroblasts exhibit a rapid rate of cell division and protein secretion.

25 **5.2. REMOVAL OF THE EXTRACELLULAR MATRIX FROM
 THE FRAMEWORK**

After the cells have been inoculated onto the framework and cultured under conditions favoring cellular growth, such that a desired amount of extracellular matrix is

30 secreted on to the three-dimensional framework, the cells are killed and the naturally secreted extracellular matrix is processed further.

This involves first killing the cells and removing the killed cells and any cellular debris from the three-dimensional framework. This process is carried out in a number of different ways. For example, the cells can be
5 killed by flash-freezing the living stromal tissue prepared in vitro in liquid nitrogen without a cryopreservative. Another way to kill the cells is to irrigate the inoculated three-dimensional framework with sterile water, such that the cells burst in response to osmotic pressure. Once the cells have been killed, one can, for example, disrupt the cellular
10 membranes and remove the cellular debris by a mild detergent rinse, such as EDTA, CHAPS or a zwitterionic detergent, followed by treatment with a cryoprotectant such as DMSO, propylene glycol, butanediol, raffinose, polyvinyl pyrrolidone, dextran or sucrose and vitrified in liquid
15 nitrogen.

Alternatively, the framework can be subjected to enzymatic digestion and/or extracting with reagents that break down the cellular membranes and allow removal of cell contents. Examples of detergents include non-ionic
20 detergents (for example, TRITON X-100, octylphenoxy polyethoxyethanol, (Rohm and Haas); BRIJ-35, a polyethoxyethanol lauryl ether (Atlas Chemical Co.), TWEEN 20, a polyethoxyethanol sorbitan monolaureate (Rohm and Haas), LUBROL-PX, or polyethylene lauryl ether (Rohm and Haas)); and ionic detergents (for example, sodium dodecyl
25 sulphate, sulfated higher aliphatic alcohol, sulfonated alkane and sulfonated alkylarene containing 7 to 22 carbon atoms in a branched or unbranched chain). Enzymes can be used also and can include nucleases (for example, deoxyribonuclease and ribonuclease), phospholipases and
30 lipases. An advantage to using a mild detergent rinse is that it will solubilize membrane-bound proteins, which are often highly antigenic.

In addition, methods well known in the art for the removal of collagens in a deposited extracellular matrix from a natural body tissue, such as a heart valve, are found in U.S. Patent No. 4,801,299 to Brendel et al., the disclosure of which is incorporated by reference herein. Such methods are also applicable in the present invention for removing the deposited extracellular matrix from the three-dimensional framework.

Once the cells have been killed and cellular debris has been removed, the collection of the naturally secreted human extracellular matrix can be accomplished in a variety of ways which depend on whether the three-dimensional framework is composed of material that is biodegradable or non-biodegradable. For example, if the framework is composed of non-biodegradable material, one can remove the extracellular matrix from a non-biodegradable support by subjecting the three-dimensional framework to sonication, or to high pressure water jets, or to mechanical scraping, or to a mild treatment with detergents and/or enzymes to remove the attached extracellular matrix from the framework.

If the extracellular matrix is deposited on a biodegradable three-dimensional framework, after killing and removing the cells and cellular debris, the extracellular matrix can be recovered, for example, by simply allowing the framework to degrade in solution, i.e., allow the framework to dissolve, thus freeing the extracellular matrix.

Additionally, if the biodegradable support is composed of a material which can be injected, like the extracellular matrix itself, one can process the entire extracellular matrix coated framework into syringes for injection or process the framework for coating or sealing a prosthetic device.

Further, if the extracellular matrix is deposited on a biodegradable support, the matrix can be removed by the same methods as if the matrix had been deposited on a non-

biodegradable support, i.e., by subjecting the three-dimensional framework to sonication, or to high pressure water jets, or to mechanical scraping, or to a mild treatment with detergents and/or enzymes to remove the attached
5 extracellular matrix from the framework. None of the removal processes are designed to damage and/or denature the naturally secreted human extracellular matrix produced by the cells.

10 5.3. FORMULATION AND USE OF EXTRACELLULAR MATRIX PREPARATIONS

5.3.1. INJECTABLE PREPARATIONS

Once the naturally secreted extracellular matrix has been collected, it is processed for use in injectable preparations to repair skin or tissue defects. The
15 extracellular matrix can be homogenized to fine particles, such that it can pass through a surgical needle. Homogenization is well known in the art, for example, by sonication. The extracellular matrix can be native, i.e., not cross-linked, or the extracellular matrix can be cross-
20 linked by any method known in the art. In a preferred embodiment, the matrix is cross-linked by gamma irradiation without the use of chemical cross-linking agents, such as glutaraldehyde, which are toxic. The gamma irradiation should be a minimum of 20 M rads to sterilize the material since all bacteria, fungi, and viruses are destroyed at 0.2 M
25 rads. Preferably, the extracellular matrix can be irradiated from 0.25 to 2 M rads to sterilize and cross-link the extracellular matrix.

Further, the amounts and/or ratios of the collagens and other proteins may be adjusted by mixing extracellular
30 matrices secreted by other cell types prior to placing the material in a syringe. For example, biologically active substances, such as proteins and drugs, can be incorporated

in the compositions of the present invention for release or controlled release of these active substances after injection of the composition. Exemplary biologically active substances can include tissue growth factors, such as TGF- β , and the like which promote healing and tissue repair at the site of the injection. Alternatively, genetically engineered cells which express a biologically active substance can be incorporated into the compositions of the present invention.

Final formulation of the aqueous suspension of naturally secreted human extracellular matrix will typically involve adjusting the ionic strength of the suspension to isotonicity (i.e., about 0.1 to 0.2) and to physiological pH (i.e., about pH 6.8 to 7.5) and adding a local anesthetic, such as lidocaine, (usually at a concentration of about 0.3% by weight) to reduce local pain upon injection. The final formulation will also typically contain a fluid lubricant, such as maltose, which must be tolerated by the body. Exemplary lubricant components include glycerol, glycogen, maltose and the like. Organic polymer base materials, such as polyethylene glycol and hyaluronic acid as well as non-fibrillar collagen, preferably succinylated collagen, can also act as lubricants. Such lubricants are generally used to improve the injectability, intrudability and dispersion of the injected biomaterial at the site of injection and to decrease the amount of spiking by modifying the viscosity of the compositions. This final formulation is by definition the processed extracellular matrix in a pharmaceutically acceptable carrier.

In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or

vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum oil such as mineral oil, vegetable oil such as peanut oil, soybean oil, and
5 sesame oil, animal oil, or oil of synthetic origin. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol
10 monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The therapeutic composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of
15 solutions, suspensions, emulsion, powders, sustained-release formulations and the like. The composition can be formulated with traditional binders and carriers such as triglycerides. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such
20 compositions contain a therapeutically effective amount of the therapeutic composition, together with a suitable amount of carrier so as to provide the form for proper administration to the subject. The formulation should suit the mode of administration.

The formulated matrix and carrier composition is
25 subsequently placed in a syringe or other injection apparatus for precise placement of the matrix at the site of the tissue defect. In the case of formulations for dermal augmentation, the term "injectable" means the formulation can be dispensed from syringes having a gauge as low as 25 under normal
30 conditions under normal pressure without substantial spiking. Spiking can cause the composition to ooze from the syringe rather than be injected into the tissue. For this precise

placement, needles as fine as 27 gauge (200 μ I.D.) or even 30 gauge (150 μ I.D.) are desirable. The maximum particle size that can be extruded through such needles will be a complex function of at least the following: particle maximum
5 dimension, particle aspect ratio (length:width), particle rigidity, surface roughness of particles and related factors affecting particle:particle adhesion, the viscoelastic properties of the suspending fluid, and the rate of flow through the needle. Rigid spherical beads suspended in a
10 Newtonian fluid represent the simplest case, while fibrous or branched particles in a viscoelastic fluid are likely to be more complex.

The above described steps in the process for preparing injectable naturally secreted human extracellular matrix are preferably carried out under sterile conditions
15 using sterile materials. The processed extracellular matrix in a pharmaceutically acceptable carrier can be injected intradermally or subcutaneously to augment soft tissue, to repair or correct congenital anomalies, acquired defects or cosmetic defects. Examples of such anomalies or defects
20 include but are not limited to congenital anomalies as hemifacial microsomia, malar and zygomatic hypoplasia, unilateral mammary hypoplasia, pectus excavatum, pectoralis agenesis (Poland's anomaly) and velopharyngeal incompetence secondary to cleft palate repair or submucous cleft palate (as a retropharyngeal implant); acquired defects
25 (post-traumatic, post-surgical, post-infectious) such as depressed scars, subcutaneous atrophy (e.g., secondary to discoid lupis erythematosus), keratotic lesions, enophthalmos in the unucleated eye (also superior sulcus syndrome), acne pitting of the face, linear scleroderma with subcutaneous
30 atrophy, saddle-nose deformity, Romberg's disease and unilateral vocal cord paralysis, post-surgical incisions including amputations; and cosmetic defects such as glabellar

frown lines, deep nasolabial creases, circum-oral geographical wrinkles, sunken cheeks and mammary hypoplasia. In specific embodiments, the compositions of the present invention can be used to correct abnormal skin pigmentation, or encourage hair growth and/or retention, or to fill in skin biopsy areas to minimize scar formation.

The processed extracellular matrix compositions of the present invention can also be injected into internal tissues, such as the tissues defining body sphincters, e.g., to augment such tissues. Such internal tissues also include arteries and veins, such that the compositions can be used to fill in the sac of an aneurysm, or cardiac chamber, or to plug a hole in a blood vessel wall made by, for example, the insertion of a stent, catheter or angioplasty device. Furthermore, once a vascular stent or graft has been inserted into the lumen of an artery at the site of an aneurysm to provide structural integrity as well as to provide an alternative path for fluid at the site, the compositions of the present invention can be used to fill in the remaining sac space to provide further structural integrity.

20

5.3.2. IMPLANTABLE PREPARATIONS

The collected naturally secreted extracellular matrix can also be processed for use in coating or sealing a prosthetic device, for example, an implantable device such as a stent. The extracellular matrix can be homogenized to fine particles, such that it can be processed into a slurry or a suspension. Homogenization is well known in the art, for example, by sonication. Further, the extracellular matrix can be cross-linked by any method known in the art. In a preferred embodiment, the extracellular matrix can be cross-linked by gamma irradiation without the use of chemical cross-linking agents, such as glutaraldehyde, which are toxic. The presence of crosslinks aids in preserving the

25

30

integrity of the coating and rendering it resistant to indigenous enzymes which would otherwise weaken it. The gamma irradiation should be a minimum of 20 M rads to sterilize the material since all bacteria, fungi, and viruses are destroyed at 0.2 M rads. Preferably, the extracellular matrix can be irradiated from 0.25 to 2 M rads to sterilize and cross-link the extracellular matrix.

Further, the amounts and/or ratios of the collagens and other proteins may be adjusted by mixing extracellular matrices secreted by other cell types prior to coating the material onto a device. Biologically active substances, such as proteins and drugs, can also be incorporated in the compositions of the present invention for release or controlled release of such active substances after implantation of the device. Exemplary biologically active substances include tissue growth factors, such as α -FGF, β -FGF, NGF, EGF, HGF, TGF- β , angiogenesis factors, e.g., VEGF, and the like, which promote healing and tissue repair at the site of placement of the device. The extracellular matrix compositions can also be formulated with live cells, including mesenchymal stem cells or genetically engineered cells, to provide factors that, e.g., facilitate healing and repair.

Final formulation of the slurry or aqueous suspension of naturally secreted human extracellular matrix can involve adjusting the ionic strength of the suspension to isotonicity (i.e., about 0.1 to 0.2) and to physiological pH (i.e., about pH 6.8 to 7.5). The final formulation will also typically contain a fluid lubricant, such as maltose, which allows for ease of applying the matrix composition to the device by spraying. Exemplary lubricant components include glycerol, glycogen, maltose and the like. Organic polymer base materials, such as polyethylene glycol and hyaluronic acid as well as non-fibrillar collagen, preferably

succinylated collagen, can also act as lubricants. Such lubricants are generally used to improve the dispersion of the matrix composition onto the device and to decrease the amount of spiking by modifying the viscosity of the compositions. This final formulation is by definition the processed extracellular matrix in a pharmaceutically acceptable carrier. Moreover, once formulated, the composition can be lyophilized and processed as a powder. Based on the teaching of the present invention, the exact formulation may be determined empirically by one of skill in the art.

In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum oil such as mineral oil, vegetable oil such as peanut oil, soybean oil, and sesame oil, animal oil, or oil of synthetic origin. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The therapeutic composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, powders, and the like. The composition can be formulated with traditional binders and

carriers such as triglycerides. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions contain an effective amount of the matrix composition, together with a suitable amount of carrier so as to provide the proper physical form for application to a device.

In a preferred embodiment, the matrix composition is formulated in accordance with routine procedures as a composition adapted for application to suture. Such exemplary formulations include, but are not limited to, an ointment or salve or other viscous solution. In another preferred embodiment, the matrix composition is formulated in accordance with routine procedures as a composition adapted for application to a synthetic vascular graft.

In an alternative embodiment, the extracellular matrix is formulated with a hydrogel polymer. In an aspect of this embodiment, the matrix is mixed with a hydrogel, or in another aspect, placed on the surface of a hydrogel, before the hydrogel is placed at a desired site within or on a subject, and subsequently polymerized, either *in situ* or *in vitro*. Such hydrogel polymers are well known in the art and are described in, for example, International Patent Publication WO 98/52543, published November 26, 1998, incorporated herein by reference in its entirety. These matrix/hydrogel compositions are useful in the repair of spinal or craniofacial defects. For example, when surgery is performed on the brain, a portion of the skull is typically excised or is displaced by drilling. In such cases, a fine screen (e.g., metal, plastic or a polymer), which is porous enough to allow cellular infiltration, but prevents particulate matter and the bone regenerative material to enter the skull, is inserted between the brain and a particulate bone-forming composition that repairs the skull. In one aspect of this embodiment, the metal screen is coated

with a matrix/hydrogel composition and polymerized. In another aspect of this embodiment, the matrix/hydrogel is polymerized and placed on top of the screen. In an alternative aspect of this embodiment of the invention, a
5 matrix/hydrogel composition is used instead of the metal screen. In any of these aspects, cells, including genetically modified cells, and drugs and/or growth factors can be added to the matrix/hydrogel composition before polymerization to facilitate healing. In a preferred aspect, the matrix/hydrogel composition is added directly to the
10 excised area of the skull and polymerized *in situ*. In yet another preferred aspect, the matrix/hydrogel composition is added to a mold in the shape of the excised piece of skull, polymerized, and then implanted into the excised site. The matrix/hydrogel compositions are also useful in creating
15 fusions of adjacent vertebrae of the spine. In one exemplary aspect, the matrix/hydrogel composition and cells, drugs and/or growth factors are polymerized together in a mold, and the polymerized composition is used in addition to, or as a replacement of, the screen.

20 The above described steps for preparing naturally secreted human extracellular matrix compositions for coating a device are preferably carried out under sterile conditions using sterile materials. The processed extracellular matrix can be applied to at least one surface of a prosthetic device by any method known in the art, such as, e.g., spraying,
25 dipping, etc.

Exemplary devices that can be coated or sealed with a formulated human naturally secreted extracellular matrix of the present invention include, but are not limited to, a metal implant, such as a metal hip joint, cranial plate,
30 orthopedic plate, pin or screw, as well as an orthodontic pin. The device can also be the exterior of an artificial heart. The device can also be an artificial tendon or

ligament. The device can also be a vascular plug which is used to plug a hole in a blood vessel wall made by, for example, the insertion of a stent, catheter or angioplasty device.

5 Other exemplary devices are a stent or stent/graft, or a commercial synthetic vascular graft or a biologic vascular graft. Any stent, stent/graft or tissue engineered vascular graft ("tubes") known in the art can be coated or sealed with the matrix compositions of the present invention. The tubes can be metallic, or made from a biocompatible
10 polymer, as well as a biodegradable polymer, such as, e.g., dacron polyester, poly(ethylene terephthalate), polycarbonate, polymethylmethacrylate, polypropylene, polyalkylene oxalates, polyvinylchloride, polyurethanes, polysiloxanes, nylons, poly(dimethyl siloxane),
15 polycyanoacrylates, polyphosphazenes, poly(amino acids), ethylene glycol I dimethacrylate, poly(methyl methacrylate), poly(2-hydroxyethyl methacrylate), poly(HEMA), polyhydroxyalkanoates, polytetrafluorethylene, polycarbonate, poly(glycolide-lactide) co-polymer, polylactic acid, poly(ϵ -
20 caprolactone), poly(β -hydroxybutyrate), polydioxanone, poly(γ -ethyl glutamate), polyiminocarbonates, poly(ortho ester), polyanhydrides, alginate, dextran, chitin, cotton, polyglycolic acid, polyurethane, or derivatized versions thereof, i.e., polymers which have been modified to include,
25 for example, attachment sites or cross-linking groups in which the polymers retain their structural integrity while allowing for attachment of molecules, such as proteins, nucleic acids, and the like. The tubes can also be fabric-coated metal structures. The tubes can also be made from combinations of metal and polymer. The tubes can be
30 configured into any desired shape or conformation, such as, for example, linear, tapered, bifurcated, etc., and may be prepared using fiber technology, such as, e.g., crimped,

woven, knitted, velour, double velour, with or without coils. For a general review of fiber technology, see Shalaby, Fabrics, in: *Biomaterials Science, An Introduction to Materials in Medicine*, Ratner et al., eds., Academic Press, NY, 1996, pp. 118-123. The tubes can also be prepared by chemical extrusion, casting or molding using, for example, porous materials having linear or random pores that are circular or geometric in shape. In a preferred embodiment, the tubes can also be prepared using living three-dimensional stromal tissues, as described in U.S. Patent Nos. 4,963,489; 5,266,480; and 5,792,603. In a preferred embodiment, a tissue engineered vascular graft, which can be coated with a extracellular matrix composition of the invention, is prepared according to the method described in U.S. Patent Nos. 4,963,489; 5,266,480; and 5,792,603.

Further examples of devices which can be coated in accordance with the present invention include, but are not limited to, mechanical heart valves, such as unmounted, free style, or pericardial valves, tilting disk and central flow disk; biological xenogeneic or allogeneic heart valves, such as preserved homografts and stent-mounted porcine valve heterografts; and annuloplasty rings and bands. For example, in one embodiment of the invention, a xenogeneic heart valve obtained from a bovine source is coated with the extracellular matrix of the present invention such that infiltration and colonization of host cells now occurs. Additionally, since mechanical heart valves are typically made of metal or a metal alloy, the mechanical valve is placed within a sewing ring that allows for suturing of the valve to the supporting tissue in the patient. Thus, a sewing ring can also be coated or sealed with a human naturally secreted extracellular matrix composition in accordance with the present invention such that wound healing is facilitated and cellular migration and infiltration is

promoted, which in turn reduces scar tissue formation. Other types of artificial heart valves that can be coated with the matrix composition of the present invention are described in International Patent Publication WO 96/08213, published March 5 21, 1996.

Additional examples of devices are gauze pads or adhesive bandages. The matrix compositions of the present invention can be applied to a gauze pad or a gauze pad on an adhesive bandage to promote wound healing. The matrix compositions can also be applied to suture material (thread) 10 for internal and external stitches, as well as being added to cosmetics, cuticle cream for nails, shampoo or conditioner for hair, body lotion, lip balm, antibiotic gels, ointments, and added to powders.

There are a variety of methods of manufacture 15 available to provide a prosthetic device, coated on at least one surface with a sufficient amount of a naturally secreted human extracellular matrix, useful in the present invention. The resulting coating is preferably uniform and must be integral so that contact between the device surface(s) and 20 the surrounding tissue is precluded. Once the extracellular matrix has been collected and formulated, the matrix can be applied to the device by spraying at least one surface of the device with the matrix in suspension, and allowing the applied surface to dry. In another embodiment, the device can be dipped into such a suspension, or by casting a 25 suspension of the matrix over the device, or by layering a device the a suspension of the matrix over the device, or by impregnating a device with a suspension of the extracellular matrix. In a specific embodiment, a formulated extracellular matrix is applied to the outside surface of a tube. By 30 applying the extracellular matrix on the outside of the tube, the growth factors and proteins present in the extracellular matrix promote host cell integration, wound healing and/or

angiogenesis. In yet another specific embodiment, a formulated extracellular matrix is applied to the inside surface of a tube. By applying the matrix on the inside of the tube, the growth factors and proteins present in the
5 matrix promote reendothelialization of the lumen wall, promote wound healing and/or prevent one or more cardiovascular disease states, such as stenosis, restenosis or intimal and neointimal hyperplasias. In yet another embodiment, the extracellular matrix is applied to both the
10 outside and the inside surfaces of the device.

In another embodiment, a space is provided between the coating and the original prosthetic device. This can be accomplished by using a mold which has been coated with the extracellular matrix suspension, which mold is slightly larger than the prosthetic device to be coated. For example,
15 in one aspect of this embodiment, a model prosthesis is enhanced in size by coating of, for example, paraffin. Thus, the enlarged prosthesis is then used as a model for a two-piece mold of casting resin which can be split away into the two halves after solidifying around the enlarged prosthesis.
20 The mold is then washed and each half supplied with a sufficient amount of the matrix suspension so that when a new prosthesis is inserted and the mold resealed around it, the matrix suspension spreads over the entire surface to form a uniform coating. After sealing, the assembly is incubated to
25 solidify partially the matrix layer. After removing the mold, any uncoated areas of the device are covered with additional extracellular matrix.

In an alternative embodiment, before the surface of the device is coated or sealed with an extracellular matrix composition of the present invention, the surface of the
30 device can be derivatized with an attachment moiety. For example, an antibody or a small molecule capable of binding to a component of the matrix composition can be attached to a

surface of a device prior to the application of the matrix composition.

The particular amount of the extracellular matrix preparation to be applied to the device can be easily
5 determined empirically by comparing devices with different amounts of the matrix coated thereon and determining the efficacy of each by, for example, measuring tissue regeneration and/or reepithelialization. Also, one skilled in the relevant art and who is familiar with standard
10 treatments would also be in a position to easily evaluate the efficacy of a device coated with an amount of the extracellular matrix. In an exemplary embodiment, the thickness of extracellular matrix applied to a device is in the range of about 1 to 100 microns. In a preferred
15 embodiment, the thickness is in the range of about 1-50 microns. In a more preferred embodiment, the thickness is in the range of about 10 to 30 microns. In an even more preferred embodiment, the thickness is in the range of about 20-25 microns. Moreover, more than one coat of the extracellular matrix, either untreated or crosslinked, can be
20 applied to a device. It is highly desirable to inspect the device once coated to insure that there are no gaps or breaks present in the coating.

In a specific embodiment, a synthetic vascular graft which is coated on the exterior surface with the naturally secreted human extracellular matrix of the present
25 invention, and which provides a reservoir for the slow release of a drug after implantation, is provided. The extracellular matrix proteins in the graft are complexed with a drug, such as an antibiotic agent or an antiviral agent, or mixtures thereof, in order to insure against graft rejection.
30 In yet another aspect, the extracellular matrix proteins are complexed with a drug, such as an angiogenesis factor, to insure that the implant or graft helps to promote tissue

regeneration and angiogenesis.

The methods used for implanting the devices coated with the human naturally secreted extracellular matrix are analogous to those used for the implantation of such devices without the extracellular matrix coating, and, of course, depend on the nature of the condition to be modified or corrected. The surgery can be performed under either local or systemic anesthesia and, generally, involves an incision, spacing to accommodate the implant, insertion, and suture.

Various sample embodiments of the invention are described in the sections below. For purposes of description only, and not by way of limitation, the three-dimensional culture system of the invention is described based upon the type of tissue and cells used in various systems. These descriptions specifically include but are not limited to bone marrow, skin, smooth muscle cells, epithelial cells, and cartilage but it is expressly understood that the three-dimensional culture system can be used with other types of cells and tissues. The invention is also illustrated by way of examples, which demonstrate characteristic data generated for each system described.

EXAMPLES

6. EXAMPLE:THREE-DIMENSIONAL SKIN STROMAL CULTURE SYSTEM

The subsections below describe the three-dimensional culture system of the invention for culturing different stromal cells *in vitro*. Briefly, cultures of fibroblasts were established on nylon mesh which had been previously sterilized. Within 6-9 days of incubation, adherent fibroblasts began to grow into the meshwork openings and deposited parallel bundles of collagen. Indirect immunofluorescence using monoclonal antibodies showed predominantly type I collagen with some type III as

well.

6.1. ESTABLISHMENT OF THE THREE-DIMENSIONAL STROMA OF SKIN FIBROBLASTS

5 Skin fibroblasts were isolated by mincing dermal tissue, trypsinization for 2 hours, and separation of cells into a suspension by physical means. Fibroblasts were grown to confluency in 25 cm² Falcon tissue culture dishes and fed with RPMI 1640 (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), fungizone, gentamicin, and
10 penicillin/streptomycin. Fibroblasts were lifted by mild trypsinization and cells were plated onto nylon filtration mesh, the fibers of which are approximately 90 μ m in diameter and are assembled into a square weave with a mesh opening of 210 μ m (Tetko, Inc., NY). The mesh was pretreated with a
15 mild acid wash and incubated in polylysine and FBS. Adherence of the fibroblasts was seen within 3 hours, and fibroblasts began to stretch across the mesh openings within 5-7 days of initial inoculation. These fibroblasts were metabolically active, secreted an extracellular matrix, and
20 rapidly formed a dermal equivalent consisting of active fibroblasts and collagen. FIG. 1 is a scanning electron micrograph depicting fibroblast attachment and extension of cellular processes across the mesh opening.

6.2 ESTABLISHMENT OF THE THREE-DIMENSIONAL BONE MARROW STROMAL CULTURES

25 Bone marrow was aspirated from multiple sites on the posterior iliac crest of hematologically normal adult volunteers after informed consent was obtained. Specimens were collected into heparinized tubes and suspended in 8 ml of RPMI 1640 medium which was conditioned with 10% FBS and
30 5-10% HS and supplemented with hydrocortisone, fungizone, and streptomycin. The cell clumps were disaggregated and divided into aliquots of 5×10^6 nucleated cells.

Nylon filtration screen (#3-210/36, Tetko Inc., NY) was used as a three-dimensional framework to support all stromal cell cultures described in the examples below. The screen consisted of fibers, which were 90 μm in diameter, assembled into a square weave pattern with sieve openings of 210 μm . Stromal cells were inoculated using the protocols described in Section 6.1. Adherence and subsequent growth of the stromal elements was monitored using inverted phase contrast microscopy and scanning electron microscopy (SEM).

10

6.3 PREPARATION OF THE THREE-DIMENSIONAL ORAL MUCOSAL EPITHELIAL STROMAL MATRIX

Samples of oral mucosal tissue were obtained from orthodontic surgical specimens. Tissue was washed three times with fresh MEM containing antibiotics (2 ml of antibiotic antimycotic solution from GIBCO, Cat. #600-5240 AG; and 0.01 ml of gentamicin solution from GIBCO Cat. #600-5710 AD per 100 cc MEM), cut into small pieces, then washed with 0.02% EDTA (w/v). 0.25% trypsin (in PBS without Ca^{++} or Mg^{++}) was added; after a few seconds, the tissue pieces were removed and placed in fresh trypsin (in PBS without Ca^{++} or Mg^{++}) and refrigerated at 4°C overnight. Tissues were removed and placed in fresh trypsin solution, and gently agitated until cell appeared to form a single-cell suspension. The single-cell suspension was then diluted in MEM containing 10% heat inactivated fetal bovine serum and centrifuged at 1400x g for 7 minutes. The supernatant was decanted and the pellet containing mucosal epithelial cells was placed into seeding medium. Medium consisted of DMEM with 2% Ultrosen G, 1 X L-glutamine, 1 X non-essential amino acids, penicillin and streptomycin. The cells were seeded onto a three-dimensional framework. The three-dimensional stromal culture was generated using oral fibroblasts and 8 mm x 45 mm pieces of nylon filtration screen (#3-210/36, Tetko Inc., NY). The

30

mesh was soaked in 0.1 M acetic acid for 30 minutes and treated with 10 mM polylysine suspension for 1 hour. The meshes were placed in a sterile petri dish and inoculated with 1×10^6 oral fibroblasts collected as described above in DMEM complete medium. After 1-2 hours of incubation at 5% CO_2 , the meshes were placed in a Corning 25 cm^2 tissue culture flask, floated with an additional 5 ml of medium, and allowed to reach subconfluence, being fed at 3 day intervals. Cultures were maintained in DMEM complete medium at 37°C and 5% CO_2 in a humidified atmosphere and were fed with fresh medium every 3 days.

6.4 ESTABLISHMENT OF THE THREE DIMENSIONAL SMALL VESSEL ENDOTHELIAL STROMAL CELL CULTURE

Small vessel endothelial cells isolated from the brain according to the method of Larson et al., 1987, Microvasc. Res. 34:184 were cultured in vitro using T-75 tissue culture flasks. The cells were maintained in Dulbecco's Modified Eagle Medium/Hams-F-12 medium combination (the solution is available as a 1:1 mixture). The medium was supplemented with 20% heat-inactivated fetal calf serum (FCS), glutamine, and antibiotics. The cells were seeded at a concentration of 1×10^6 cells per flask, and reached a confluent state within one week. The cells were passaged once a week, and, in addition, were fed once a week with DMEM/Hams-F-12 containing FCS, glutamine, and antibiotics as described. To passage the cells, flasks were rinsed twice with 5 ml of PBS (without Ca^{++} or Mg^{++}) and trypsinized with 3 ml of 0.05% Trypsin and 0.53 mM EDTA. The cells were pelleted, resuspended, and tested for viability by trypan blue exclusion, seeded and fed with 25 ml of the above mentioned DMEM/Hams-F-12 supplemented medium. A factor VIII related antigen assay, Grulnick et al., 1977, Ann. Int. Med. 86:598-616, is used to positively identify endothelial cells,

and silver staining was used to identify tight junctional complexes, specific to only small vessel endothelium.

Nylon filtration screen mesh (#3-210/36, Tetko, Inc., NY) was prepared essentially as described above. The mesh was soaked in an acetic acid solution (1 ml glacial acetic acid plus 99 ml distilled H₂O) for thirty minutes, was rinsed with copious amounts of distilled water and then autoclaved. Meshes were coated with 6 ml fetal bovine serum per 8 x 8 cm mesh and incubated overnight. The meshes were then stacked, three high, and 3 x 10⁷ small vessel endothelial cells (cultured as described) were seeded onto the stack, and incubated for three hours at 37°C under 5% CO₂ in a humidified atmosphere. The inoculated meshes were fed with 10 ml of DMEM/Hams-F-12 medium every 3-4 days until complete confluence was reached (in approximately two weeks).

6.5 ESTABLISHMENT OF THE THREE DIMENSIONAL CHONDROCYTE STROMAL CELL CULTURE

Cartilage was harvested from articular surfaces of human joints. The cartilage pieces were digested with collagenase (0.2% w/v) in complete medium (DMEM with 10% fetal bovine serum, glutamine, non-essential amino acids, sodium pyruvate, 50 µg/ml ascorbate and 35 µg/ml gentamicin) for 20 hours at 37°C. Liberated chondrocytes were spun, resuspended in complete medium, counted and plated at 1 x 10⁶ cells per T-150 flask. Cells were routinely passed at confluence (every 5-7 days).

Polyglycolic acid mesh (1 mm diameter x 2 mm thick) was sterilized by ethylene oxide or electron beam treatment and presoaked overnight in complete medium. The mesh was seeded in 6 well plates with 3-4 x 10⁶ cells per mesh in a total volume of 10 µl and incubated for 3-4 hours at 37°C in a tissue culture incubator. At this time, 1.5 ml of media was added. The seeded mesh was incubated overnight. 5 ml of

media was added the next day. Media was changed three times per week until confluence is reached.

7. EXAMPLE: EXTRACELLULAR MATRIX COMPOSITION

5 The extracellular matrix has been characterized by
a number of analytic methods to determine its content of
matrix proteins, each value is the average of at least two
independent determinations. The matrix contained type I and
type III collagens, fibronectin, tenascin, sulfated
glycosaminoglycans, decorin and various other secreted human
10 extracellular matrix proteins. Additionally, the secreted
matrix proteins were found throughout the three-dimensional
support framework. The extracellular matrix contained a
total protein amount of $292 \text{ mg/cm}^2 \pm 0.06$; fibronectin was
present at $3.4 \text{ mg/cm}^2 \pm 1.2$; and tenascin at $1.7 \text{ mg/cm}^2 \pm 0.6$.
15 Both fibronectin and tenascin showed the expected molecular
weight distributions on immunoblots.

7.1. COLLAGEN CONTENT OF THE EXTRACELLULAR MATRIX

20 Collagen content of the extracellular matrix was
determined using the Sirius Red assay. The binding of Sirius
Red F3BA in saturated picric acid solution has been used
widely to estimate fibrotic collagen deposition. Bedossa et
al., 1989, Digestion 44(1):7-13; Finkelstein et al., 1990,
Br. J. Ophthalmol. 74(5):280-282; James et al., 1990, Liver
25 10(1):1-5. The specificity of Sirius Red binding to collagen
is based largely on its use as a histological stain. In rat
liver with various degrees of cholestatic fibrosis, collagen
content measured by Sirius Red binding shows strong
correlation with hydroxyproline content. Walsh et al., 1992,
30 Analyt. Biochem. 203:187-190. In addition, histological
staining with Sirius Red is birefringent, indicating
directional binding related to the orientation of the

collagen strands. Sirius Red is known to bind to proteins other than the classical collagens that contain collagen-like triple helices, such as the complement component C1. Some minor binding to serum albumin has also been found, although control experiments using bovine serum albumin standard showed no interference with the assay. The interference is estimated to represent less than 2% of the collagen signal in the extracellular matrix and the use of Sirius Red assay gives a reproducible method for measuring collagens. The extracellular matrix contained a collagen content of 0.61 mg/cm² ± 0.09. Further, collagens I and III showed the expected molecular weight distributions on immunoblots.

7.2. COLLAGEN FIBERS VISUALIZED VIA ELECTRON MICROSCOPY

Collagen derived from the dermal tissue grown in vitro and collagen derived from a normal adult human dermal sample were processed and visualized by transmission electron microscopy (TEM). Briefly, the respective collagens were weighed and placed in a sterile 50 ml centrifuge tube with 30 ml 0.05 M Tris buffer, pH 8.0. After mixing for two hours on a wrist shaker, the Tris buffer was removed and the specimen placed in a homogenization cylinder along with 30 ml fresh 0.05 M Tris buffer. The sample was homogenized for 30 seconds in buffer alone and then for two 30 second bursts following the addition of a dispersing agent as described in U.S. Patent No. 4,969,912 and 5,332,802. The temperature was maintained at 5-10°C during the mechanical disruption process. The dispersing agent was added at a concentration of 0.05% (wet weight of the collagen). The homogenized preparation was centrifuged at 3500 rpm for 6 minutes to separate the dispersed collagenous material from the yet undispersed material. The undispersed residue was again treated with dispersing agent at 0.05% (wet weight of the

collagen) and homogenized for two 30 second bursts. The dispersion was again centrifuged to recover dispersed collagenous material which was added to the first recovery.

The collagenous dispersion was filtered through a 100 micron filter, centrifuged at 3500 rpm and the pellet was washed 3 times with 0.004 M phosphate buffer, pH 7.4. The last centrifugation was conducted at 10,000 rpm to pack the collagenous pellet. Samples were then collected for TEM. As shown in Figures 2A-D, the collagen fibers isolated from either the extracellular matrix prepared from dermal tissue grown *in vitro* (Figures 2A-B) or from normal adult human dermis (Figures 2C-D) appeared identical in that intact collagen fibers with typical collagen banding and normal periodicity in both preparations.

7.3. GLYCOSAMINOGLYCANS PRESENT IN THE EXTRACELLULAR MATRIX

Glycosaminoglycans have been shown to play a variety of structural and functional roles in the body and their presence in the secreted extracellular matrix is important. Table II lists a number of examples of glycosaminoglycans which have been determined to be found in the extracellular matrix as well as their functional importance in normal dermis.

TABLE II

NAME	LOCATION	GLYCAN	FUNCTION	MECHANISM
Versican	Matrix	12-15 Chondroitin sulfate	Structural	Binds hyaluronic acid and collagen
Decorin	Matrix	1 Chondroitin/dermatan sulfate	Binding TGF- β and other growth factors; binds to collagen	Inactivates growth factors

Betaglycan	Cell membrane	1-4 Chondroitin/heparan sulfate	TGF- β Type III receptor	Adjunct receptor for TGF β
Syndecan	Cell membrane	1-3 Chondroitin sulfate, 1-2 heparan sulfate	Growth factor binding	

5

Further, the extracellular matrix was found to contain a total of 2.8 mg/cm² \pm 0.1 sulfated glycosaminoglycans.

10 7.4. GROWTH FACTORS PRESENT IN THE EXTRACELLULAR MATRIX

The cells producing and depositing the extracellular matrix also expressed a number of different growth factors. Growth factors are important in the extracellular matrix for two reasons. During the growth of
15 and deposition of the extracellular matrix, naturally seeded growth factors help to control cell proliferation and activity. Further, growth factors remain attached to the extracellular matrix. A variety of growth factors have been determined to be expressed during the deposition of the
matrix.

20

The expression of growth factors has been examined by polymerase chain reaction of reverse transcripts (RT-PCR) of total RNA. Briefly, RNA was extracted from the growing cells by an SDS precipitation and organic solvent partition procedure. The RNA was transcribed using superscript reverse
25 transcriptase and random hexamer primers. The same batch of reverse transcript was used for detection of all the growth factors. PCR was performed under standard conditions, using 4 μ l reverse transcript, corresponding to 200 ng RNA in a total volume of 20 μ l.

30

Based on this assay, acidic and basic FGF, TGF- α and TGF- β , and KGF mRNA transcripts were present as were several others as shown in Table III, including PDGF, amphiregulin, HBEGF, IGF, SPARC and VEGF. Of these, PDGF and

TGF- β 3 are thought to be involved in regulation of cell proliferation and matrix deposition in culture, while TGF- β 1, HBEGF, KGF, SPARC, VEGF and decorin are deposited in the matrix. Amphiregulin, IGF-1, IGF-2 and IL-1 were not
 5 expressed at the sensitivity used in these experiments.

TABLE III

	Messenger RNA	Full Name	Function	Expression
10	PDGF-A Chain	Platelet-derived growth factor, A chain	Mitogen for fibroblasts, granulation tissue, chemotactic	++
15	PDGF-B Chain	Platelet-derived growth factor, B chain	Mitogen for fibroblasts, granulation tissue, chemotactic	0 - (+)*
	IGF-1	Insulin-like growth factor-1	Mitogen for fibroblasts	0
20	IGF-2	Insulin-like growth factor-2	Mitogen for fibroblasts	(+)
	TGF- α	Transforming growth factor- α	Mitogen for fibroblasts, keratinocytes	+
25	Amphiregulin	Amphiregulin	Mitogen for fibroblasts, keratinocytes	0
	KGF	Keratinocyte growth factor	Mitogen for keratinocytes	++
30	HBEGF	Heparin-binding epidermal growth factor-like growth factor	Mitogen for fibroblasts, keratinocytes	+++

TABLE III continued

	Messenger RNA	Full Name	Function	Expression
5	TGF- β 1	Transforming growth factor- β 1	Stimulates matrix deposition	+
	TGF- β 3	Transforming growth factor- β 3	Stimulates matrix deposition	++ - ++
	VEGF	Vascular endothelial growth factor	Angiogenic factor	++
10	SPARC	Secreted protein acidic and rich in cysteine	Complex anti-angiogenic, angiogenic	++++
	ICAM-1	Intercellular adhesion molecule-1	Lymphocyte adhesion, mobility	+
15	VCAM	Vascular cellular adhesion molecule	Lymphocyte adhesion, mobility	+++
	GAPDh	Glyceraldehyde 3-phosphate dehydrogenase	Glycolytic housekeeping gene	+++
20	β 2-microglobulin	β 2-microglobulin	Antigen presentation	+++

A small amount of PDGF B chain is seen in some preparations.

25

8. EXAMPLE:COLLAGEN SYNTHESIS COMPARISON

The following experiment shows that more extracellular matrix is secreted by fibroblast cells when culture on a three-dimensional framework than when cultured in traditional monolayer tissue culture dishes. Fibroblasts were cultured in monolayer 6 well plates with DMEM tissue culture medium containing 10% serum. At days 4 and 8, samples of the culture medium were taken and subjected to

30

analysis for detecting the soluble C-propeptide of collagen, which is an indirect measurement of collagen synthesis. The assay used was a commercial ELISA kit distributed by PanVera, Madison, WI. The amount of collagen synthesis on a per cell basis was calculated using the following formula: C-propeptide released (ng/ml) * 1 ml * 50 (dilution factor) / cell number / days in culture. In monolayer culture, the amount of collagen synthesized per cell is in the range of 6.5 to 16 ng/10⁶ cells/day.

Fibroblasts were also cultured on a 11 x 11 square three-dimensional framework with DMEM tissue culture medium containing 10% serum in accordance with the disclosure of the present invention. At days 2, 5 and 8 samples of the culture medium were taken and subjected to analysis for detecting the soluble C-propeptide of collagen. The assay used was a commercial ELISA kit distributed by PanVera, Madison, WI. The amount of collagen synthesis on a per cell basis was calculated using the following formula: C-propeptide released (ng/ml) * 1 ml * 50 (dilution factor) / cell number / days in culture. In three-dimensional culture, the amount of collagen synthesized per cell is in the range of 26 to 116 ng/10⁶ cells/day based on an estimate of 1.2 x 10⁶ cells per 11 x 11 square framework.

Thus, it has been determined that cells cultured on a three-dimensional framework synthesize 4-7 times more collagen as compared to cells cultured in traditional monolayer culture.

The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein

will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

A number of references are cited herein, the entire
5 disclosures of which are incorporated herein, in their
entirety, by reference.

10

15

20

25

30

What is claimed is:

1. A prosthetic device suitable for implantation or use in a human coated on at least one surface with a sufficient amount of a composition comprising a naturally
5 secreted human extracellular matrix.

2. The device according to claim 1 wherein the composition comprising a naturally secreted human extracellular matrix is produced by a method comprising:

- 10 (a) providing a living stromal tissue prepared in vitro comprising human stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework, said framework composed of a biocompatible, non-
15 living material formed into a three-dimensional structure having interstitial spaces bridged by the stromal cells;
- (b) killing the cells in the living stromal tissue;
- 20 (c) removing the killed cells and any cellular contents from the framework;
- (d) collecting the connective tissue proteins naturally secreted by the stromal cells attached to the framework; and
- 25 (e) processing the collected connective tissue proteins of step (d) with a pharmaceutically acceptable carrier, said carrier suitable for coating a prosthetic device.

3. The device according to claim 2 in which the
30 collected connective tissue proteins of step (d) are processed by homogenizing, cross-linking, or suspending the collected connective tissue proteins in a physiological

acceptable carrier prior to step (e).

4. The device according to claim 2 in which the collected connective tissue proteins of step (d) are
5 processed by adjusting ratios of collagen types I-V, respective to each other, prior to step (e).

5. The device according to claim 2 in which the stromal cells of the living stromal tissue are fibroblasts.

10 6. The device according to claim 2 in which the stromal cells of the living stromal tissue are cells found in loose connective tissue or bone marrow.

7. The device according to claim 6 in which the
15 stromal cells of the living stromal tissue are endothelial cells, pericytes, macrophages, monocytes, leukocytes, plasma cells, mast cells, chondrocytes or adipocytes.

8. The device according to claim 2 in which the
20 framework is composed of a biodegradable material.

9. The device according to claim 8 in which the biodegradable material is cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, dextran, collagen, chitosan, hyaluronic acid, nitrocellulose, alginate, poly(glycolide-
25 lactide) co-polymer, polylactic acid, poly(ϵ -caprolactone), poly(β -hydroxybutyrate), polydioxanone, poly(γ -ethyl glutamate), polyiminocarbonates, poly(ortho ester), or polyanhydride.

30 10. The device according to claim 2 in which the framework is composed of a non-biodegradable material.

11. The device according to claim 10 in which the non-biodegradable material is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, a polymethylmethacrylate, a polyethylene, a poly(ethylene terephthalate), a polyalkylene oxalate, a polyurethane, a polysiloxane, a poly(dimethyl siloxane), a polycyanoacrylate, a polyphosphazene, a poly(amino acid), a ethylene glycol I dimethacrylate, a poly(methyl methacrylate), a poly(2-hydroxyethyl methacrylate), a poly(HEMA), or a polyhydroxyalkanoate compound.

12. The device according to claim 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 in which the framework is a mesh.

13. The device according to claim 12 in which the framework has pore spaces of about 150 μm to about 220 μm .

14. The device according to claim 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 in which the framework is a weave.

15. The device according to claim 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 in which the framework is a sponge with interconnected pores of about less than 90 to about 700 microns.

16. The device according to claim 2 in which the pharmaceutically acceptable carrier contains a lubricating agent, a tissue growth factor, or combinations thereof.

17. The device according to claim 1 in which the device is selected from the group consisting of a stent, stent/graft, vascular graft, artificial heart, mechanical heart valve, annuloplasty ring, sewing ring, metal implant,

suture material, adhesive bandage and non-adhesive bandage.

18. The device according to claim 1 in which the device is a metal implant selected from the group consisting
5 of metal hip joint, metal cranial plate, metal orthopedic plate, orthopedic screw, orthopedic pin and orthodontic pin.

19. The device according to claim 1 in which the device is composed of a biodegradable material.

10 20. The device according to claim 19 in which the biodegradable material is cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, dextran, collagen, chitosan, hyaluronic acid, nitrocellulose, alginate, poly(glycolide-lactide) co-polymer, polylactic acid, poly(ϵ -caprolactone),
15 poly(β -hydroxybutyrate), polydioxanone, poly(γ -ethyl glutamate), polyiminocarbonates, poly(ortho ester), or polyanhydride.

21. The device according to claim 1 in which the
20 device is composed of a nonbiodegradable material.

22. The device according to claim 21 in which the nonbiodegradable material is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, a
25 polymethylmethacrylate, a polyethylene, a poly(ethylene terephthalate), a polyalkylene oxalate, a polyurethane, a polysiloxane, a poly(dimethyl siloxane), a polycyanoacrylate, a polyphosphazene, a poly(amino acid), a ethylene glycol I dimethacrylate, a poly(methyl methacrylate), a poly(2-
30 hydroxyethyl methacrylate), a poly(HEMA), or a polyhydroxyalkanoate compound.

23. A method for the production of a prosthetic device coated with a composition comprising a naturally secreted human extracellular matrix comprising spraying the device with a formulated naturally secreted human
5 extracellular matrix.

24. A method for the production of a prosthetic device coated with a composition comprising a naturally secreted human extracellular matrix comprising dipping the device into a formulated naturally secreted human
10 extracellular matrix.

25. The method according to claim 23 or 24 in which the device is selected from the group consisting of a stent, stent/graft, vascular graft, artificial heart,
15 mechanical heart valve, annuloplasty ring, sewing ring, metal implant, suture material, adhesive bandage and non-adhesive bandage.

26. The method according to claim 25 in which the
20 metal implant is selected from the group consisting of metal hip joint, metal cranial plate, metal orthopedic plate, orthopedic screw, orthopedic pin and orthodontic pin.

27. The method according to claim 23 or 24 in which the composition comprising the naturally secreted
25 extracellular matrix is produced by a method comprising:

(a) providing a living stromal tissue prepared in vitro comprising human stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and
30 substantially enveloping a framework, said framework composed of a biocompatible, non-living material formed into a three-

- dimensional structure having interstitial spaces bridged by the stromal cells;
- (b) killing the cells in the living stromal tissue;
- 5 (c) removing the killed cells and any cellular contents from the framework;
- (d) collecting the connective tissue proteins naturally secreted by the stromal cells attached to the framework; and
- 10 (e) processing the collected connective tissue proteins of step (d) with a pharmaceutically acceptable carrier, said carrier suitable for coating a prosthetic device.

28. The method according to claim 27 in which the
15 collected connective tissue proteins of step (d) are processed by homogenizing, cross-linking, or suspending the collected connective tissue proteins in a physiological acceptable carrier prior to step (e).

20 29. The method according to claim 27 in which the collected connective tissue proteins of step (d) are processed by adjusting ratios of collagen types I-V, respective to each other, prior to step (e).

25 30. A method for filling in the sac of an aneurysm comprising injecting a composition comprising a naturally secreted human extracellular matrix at the site of the aneurysm.

30

1/5



FIG. 1

2/5



FIG.2A

3/5



FIG.2B

4/5



FIG.2C

5/5



FIG.2D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/18461

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L27/36 A61L27/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 31944 A (VEC TEC INC) 30 November 1995 (1995-11-30)	1,17-24
Y	page 6, line 28 -page 7, line 17 example 1	1-16, 23-29
X	WO 96 39101 A (NAUGHTON GAIL K ;ADVANCED TISSUE SCIENCES INC (US)) 12 December 1996 (1996-12-12)	30
Y	page 23, line 21 -page 24, line 28 claims	1-16, 23-29
X	WO 96 08213 A (ADVANCED TISSUE SCIENCES INC) 21 March 1996 (1996-03-21) claims	1,17-22
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

24 October 2000

Date of mailing of the international search report

02/11/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Muñoz, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/18461

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 466 105 A (CORVITA CORP) 15 January 1992 (1992-01-15) abstract column 6, line 16 -column 7, line 12	1,17-22
X	US 5 716 394 A (BRUCHMAN WILLIAM CARL ET AL) 10 February 1998 (1998-02-10) column 4, line 39 -column 5, line 22	1,17-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/18461

Patent document cited in search report	Publication date	Patent family members)	Publication date
WO 9531944 A	30-11-1995	US 5643712 A AU 2517395 A AU 2595195 A EP 0759692 A WO 9531897 A US 5699793 A US 6024698 A	01-07-1997 18-12-1995 18-12-1995 05-03-1997 30-11-1995 23-12-1997 15-02-2000
WO 9639101 A	12-12-1996	US 5830708 A AU 708090 B AU 6260996 A CA 2223892 A EP 0967934 A JP 11507558 T	03-11-1998 29-07-1999 24-12-1996 12-12-1996 05-01-2000 06-07-1999
WO 9608213 A	21-03-1996	AU 700911 B AU 3585595 A AU 9521298 A CA 2199810 A EP 0781116 A JP 10511563 T NZ 293419 A	14-01-1999 29-03-1996 04-03-1999 21-03-1996 02-07-1997 10-11-1998 25-11-1998
EP 0466105 A	15-01-1992	CA 2045222 A JP 4242642 A	13-01-1992 31-08-1992
US 5716394 A	10-02-1998	AU 2369295 A CA 2186372 A EP 0757563 A JP 9512462 T WO 9529712 A US 5908449 A	29-11-1995 09-11-1995 12-02-1997 16-12-1997 09-11-1995 01-06-1999

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)